The results suggest that our cleavable stealth chimera peptide (SRL-2) could potentially serve as a targeted therapy for breast cancer by selectively binding to LRP-1 in the TME and evading immune detection due to its antifouling properties. This evidence concerns the gene LRP1 and breast carcinoma.